Queen Mary, University of London - £55m break for bone building

January 22, 2009

A spin-off company has closed a £55 million investment deal to help develop substitutes for human bone. Joost de Bruijn of the School of Engineering and Materials Science at Queen Mary, University of London, is chief executive of Progentix Orthobiology, a company developing synthetic-bone substitutes that can help trigger and accelerate bone healing and repair. Progentix has said it has signed an investment agreement with NuVasive, a medical device firm developing products for minimally disruptive surgical treatments for the spine.

Please login or register to read this article

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments

Have your say

Log in or register to post comments